XML 36 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $)
 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended
Sep. 30, 2013
Dec. 31, 2012
Oct. 31, 2009
California Institute for Regenerative Medicine [Member]
Sep. 30, 2013
California Institute for Regenerative Medicine [Member]
Sep. 30, 2012
California Institute for Regenerative Medicine [Member]
Sep. 30, 2013
California Institute for Regenerative Medicine [Member]
Sep. 30, 2012
California Institute for Regenerative Medicine [Member]
Apr. 30, 2011
CHDI Foundation, Inc. [Member]
Sep. 30, 2013
CHDI Foundation, Inc. [Member]
Sep. 30, 2012
CHDI Foundation, Inc. [Member]
Sep. 30, 2013
CHDI Foundation, Inc. [Member]
Sep. 30, 2012
CHDI Foundation, Inc. [Member]
Dec. 31, 2012
CHDI Foundation, Inc. [Member]
Mar. 31, 2012
Juvenile Diabetes Research Foundation International [Member]
Jan. 31, 2010
Juvenile Diabetes Research Foundation International [Member]
Sep. 30, 2013
Juvenile Diabetes Research Foundation International [Member]
Sep. 30, 2012
Juvenile Diabetes Research Foundation International [Member]
Sep. 30, 2013
Juvenile Diabetes Research Foundation International [Member]
Sep. 30, 2012
Juvenile Diabetes Research Foundation International [Member]
Oct. 31, 2006
Juvenile Diabetes Research Foundation International [Member]
Sep. 30, 2013
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Sep. 30, 2012
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Sep. 30, 2013
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Sep. 30, 2012
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Jun. 30, 2012
Shire AG [Member]
Targets
Jan. 31, 2012
Shire AG [Member]
Targets
Sep. 30, 2013
Shire AG [Member]
Sep. 30, 2012
Shire AG [Member]
Sep. 30, 2013
Shire AG [Member]
Product
Sep. 30, 2012
Shire AG [Member]
Apr. 30, 2013
Sigma-Aldrich Corporation [Member]
Oct. 31, 2009
Sigma-Aldrich Corporation [Member]
Jul. 31, 2007
Sigma-Aldrich Corporation [Member]
Sep. 30, 2013
Sigma-Aldrich Corporation [Member]
Sep. 30, 2012
Sigma-Aldrich Corporation [Member]
Sep. 30, 2013
Sigma-Aldrich Corporation [Member]
Sep. 30, 2012
Sigma-Aldrich Corporation [Member]
Oct. 31, 2009
Sigma-Aldrich Corporation [Member]
Upfront license fee [Member]
Sep. 30, 2013
Sigma-Aldrich Corporation [Member]
License agreement terms [Member]
Sep. 30, 2012
Sigma-Aldrich Corporation [Member]
License agreement terms [Member]
Sep. 30, 2013
Sigma-Aldrich Corporation [Member]
License agreement terms [Member]
Sep. 30, 2012
Sigma-Aldrich Corporation [Member]
License agreement terms [Member]
Oct. 31, 2009
Sigma-Aldrich Corporation [Member]
License agreement terms [Member]
Oct. 31, 2005
Dow AgroSciences [Member]
Sep. 30, 2013
Dow AgroSciences [Member]
Sep. 30, 2012
Dow AgroSciences [Member]
Sep. 30, 2013
Dow AgroSciences [Member]
Sep. 30, 2012
Dow AgroSciences [Member]
Oct. 31, 2005
Dow AgroSciences [Member]
Minimum [Member]
Oct. 31, 2005
Dow AgroSciences [Member]
Maximum [Member]
Oct. 31, 2005
Dow AgroSciences [Member]
License agreement terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                                                                                      
Aggregate number of gene targets                                                   7                                                  
Number of initial gene targets                                                   4                                                  
Number of gene targets                                                 5                                                    
Number of additional gene targets                                                 2                                                    
Research program to develop laboratory research reagents                                                         6 years       3 years                     3 years              
Upfront license fee                                                   $ 13,000,000           $ 20,000,000           $ 15,100,000                          
Potential amount to be funded for certain Shire milestones                                                         213,500,000                                            
IND or CTA submission amount                                                         8,500,000                                            
Number of products approved                                                         0                                            
Royalty revenue                                                         0         201,000 428,000 711,000 1,035,000             2,300,000             4,000,000
Deferred revenue 2,300,000 2,304,000                                                 9,500,000   9,500,000                                            
Collaboration Agreement Related Costs and Expenses       500,000 300,000 1,400,000 900,000   0 300,000 0 1,100,000                             3,500,000 2,200,000 10,300,000 3,800,000                 100,000 100,000 100,000 300,000     0 100,000 0 400,000      
Common stock, valued                                                               4,900,000                                      
Public offering, common stock shares issued                                                               636,133                                      
Royalty revenues expected to be received                                                                                     5,000,000                
Reduced royalty rate                                                               10.50%                                      
Funding available under the amended agreement                                                               25,000,000                                      
Revenue attributable to research and development                                                             1,300,000     101,000   1,351,000 1,000,000               0 400,000 0 1,300,000      
One-time license fee earned on exercise of option                                                                                       6,000,000              
Percentage of royalties to be received from sublicensing                                                                                       25.00%              
Annual fees                                                                                                 250,000.0 3,000,000  
Minimum sublicense annual fees specific reckoning period                                                                                       11 years              
Fee due                                                                                       25,300,000              
Funds due under the agreement     14,500,000                                                                                                
Agreement to receive     4 years         1 year                                                                                      
Expected amount to be received for research and development     5,200,000                                                                                                
Agreement date     Oct. 31, 2009         Apr. 30, 2011                       Oct. 31, 2006                                                              
Receivables from sale against the grant funded to entity from sale of product Two times the amount Sangamo receives in funding under the agreement                                                                                                    
Revenues under agreement                 0 300,000 0 1,100,000       0 0 0 800,000   500,000 300,000 1,200,000 900,000                                                      
Funds due under agreement               1,300,000                                                                                      
Contractual agreement termination date                     Aug. 30, 2012                                                                                
Funds due under agreement as per amendment                         2,100,000                                                                            
Grant funding amount maximum under amended agreement                             3,000,000                                                                        
Received for work performed under agreement                           $ 800,000